Skip to main content
Equibles
CVSI logo

CVSI · CV Sciences, Inc.

Track CVSI — free

Use CVSI with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.02 0.00 (-4.50%) At close · Sep 2
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company's financial operating results and accumulated deficit, amongst other factors, raise substantial doubt about the Company's ability to continue as a going concern. The Company will continue to work towards increasing revenue and operating cash flows to meet its future liquidity requirements. However, there can be no assurance that the Company will be successful in any capital-raising efforts that it may undertake, and the failure of the Company to raise additional capital could adversely affect its future operations and viability.”
View the 10-Q filed Aug 13, 2026
Market Cap
$4.52M
Shares
225.83M

CVSI metrics

69 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.02
Market cap
$4.52M

Price action

19 metrics
Price change (1W)
+11.7%
Price change (30D)
+0.0%
Price change (3M)
-33.3%
Price change (6M)
-71.4%
Price change (YTD)
-66.7%
Price change (1Y)
-50.0%
Trailing year
Price change (5Y)
-93.1%
52-week high
$0.09
52-week low
$0.02
Change from 52-week high
-77.8%
Change from 52-week low
+33.3%
Annualized volatility
232.0%
Beta
1.0
RSI (14D)
49.4
Price vs SMA 50
-2.2%
Price vs SMA 200
-42.5%
Avg volume (3M)
641,506
Relative volume
0.8
Average dollar volume
$12,927

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
225.83M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
0.3×
reciprocal yield 308.3%
EV / EBITDA
—
EV / EBIT
—
P / sales
0.3×
reciprocal yield 290.9%
P / book
2.8
reciprocal yield 35.9%
FCF yield
-11.9%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-45.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
0.5×
reciprocal yield 197.4%
EV / revenue historical average (5Y)
0.5×
reciprocal yield 197.4%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-13

Profitability

9 metrics
Gross margin
49.1%
Operating margin
-7.6%
Trailing 12 months
Net margin
-15.7%
Gross profit (TTM)
$6.26M
Operating profit (TTM)
−$969,000
Net income (TTM)
−$2.01M
Trailing 12 months
Diluted EPS (TTM)
$-0.01
FCF margin
-4.1%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.00

Growth

11 metrics
Revenue growth YoY
-17.5%
Year over year
Net income growth YoY
—
Revenue (TTM)
$12.74M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+11.3%
Year over year · more shares
Revenue CAGR (3Y)
-5.2%
Revenue CAGR (5Y)
-10.8%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-127.7%
Return on assets
-30.8%
Debt / equity
0.0
Current ratio
1.0
EBITDA (TTM)
−$872,000
Free cash flow (TTM)
−$522,000
Quick ratio
0.2
Interest coverage
-2.9
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$248,000
Latest balance sheet
Cash & equivalents
$266,000
Total assets
$6.52M
Total debt
$18,000

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$492,000
Capital expenditures (TTM)
$30,000
R&D (TTM)
$78,000
SG&A (TTM)
$7.15M
Stock compensation (TTM)
$543,000
R&D / revenue
0.6%
Stock compensation / revenue
4.3%

Ownership (13F)

3 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—

Short interest

3 metrics
Short interest
0.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
23 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1510964 CUSIP 126654102 Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)